These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 1875750)

  • 1. [Treatment of solitary toxic thyroid nodule with 131I: results in 43 patients].
    Marín JF; Maraña G; Salto L; Astigarraga B; Estrada FJ; Lucas T; Barceló B
    Med Clin (Barc); 1991 May; 96(19):730-2. PubMed ID: 1875750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up in toxic solitary autonomous thyroid nodules treated with radioactive iodine.
    Huysmans DA; Corstens FH; Kloppenborg PW
    J Nucl Med; 1991 Jan; 32(1):27-30. PubMed ID: 1988632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Follow-up of solitary autonomous thyroid nodules treated with 131I.
    Goldstein R; Hart IR
    N Engl J Med; 1983 Dec; 309(24):1473-6. PubMed ID: 6646172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Changes in thyroid volume after radioactive iodine therapy in patients with single toxic thyroid nodule].
    Gołkowski F; Jabrocka-Hybel A; Huszno B
    Przegl Lek; 2005; 62(5):284-6. PubMed ID: 16334533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of radioiodine-131 therapy in hyperfunctioning thyroid nodules: a 20 years' retrospective study.
    Ceccarelli C; Bencivelli W; Vitti P; Grasso L; Pinchera A
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):331-5. PubMed ID: 15730415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of hyperfunctioning thyroid nodules with percutaneous ethanol injection: Eight years' experience.
    Monzani F; Caraccio N; Goletti O; Casolaro A; Lippolis PV; Cavina E; Miccoli P
    Exp Clin Endocrinol Diabetes; 1998; 106 Suppl 4():S54-8. PubMed ID: 9867198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early change of thyroid hormone concentration after 131I treatment in patients with solitary toxic adenoma.
    Pirnat E; Fidler V; Zaletel K; Gaberscek S; Hojker S
    Nuklearmedizin; 2002; 41(4):178-83. PubMed ID: 12224401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis of factors affecting treatment results for toxic goiter with radioactive 131I].
    Listewnik MH
    Ann Acad Med Stetin; 2000; 46():109-21. PubMed ID: 11712298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioiodine therapy in patients with amiodarone-induced thyrotoxicosis (AIT).
    Czarnywojtek A; Czepczynski R; Ruchala M; Wasko R; Zgorzalewicz-Stachowiak M; Szczepanek E; Zamyslowska H; Bartkowiak Z; Florek E; Sowinski J
    Neuro Endocrinol Lett; 2009; 30(2):209-14. PubMed ID: 19675515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transition of nodular toxic goiter to autoimmune hyperthyroidism triggered by 131I therapy.
    Nygaard B; Faber J; Veje A; Hegedüs L; Hansen JM
    Thyroid; 1999 May; 9(5):477-81. PubMed ID: 10365679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up study of radioiodine treatment of hyperthyroidism.
    Metso S; Jaatinen P; Huhtala H; Luukkaala T; Oksala H; Salmi J
    Clin Endocrinol (Oxf); 2004 Nov; 61(5):641-8. PubMed ID: 15521969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High prevalence of side effects after recombinant human thyrotropin-stimulated radioiodine treatment with 30 mCi in patients with multinodular goiter and subclinical/clinical hyperthyroidism.
    Romão R; Rubio IG; Tomimori EK; Camargo RY; Knobel M; Medeiros-Neto G
    Thyroid; 2009 Sep; 19(9):945-51. PubMed ID: 19678745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [131I-treatment of the autonomous toxic nodule. Assessment of a fixed dose protocol].
    Abós MD; Banzo J; Razola P; García F; Prats E
    Rev Esp Med Nucl; 1999 Dec; 18(6):431-5. PubMed ID: 10611569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Results of treatment of Graves-Basedow disease with 131I at low calculated doses].
    Gómez Arnaiz N; Gómez Saez JM; Orti Llavería A; Gavaldá Mestre L; Mairal Pairó L; Soler Ramón J
    Rev Clin Esp; 1998 Feb; 198(2):57-60. PubMed ID: 9558917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transient hypothyroidism after iodine-131 therapy for Grave's disease.
    Gómez N; Gómez JM; Orti A; Gavaldà L; Villabona C; Leyes P; Soler J
    J Nucl Med; 1995 Sep; 36(9):1539-42. PubMed ID: 7658207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Thyroid diseases in sub-Saharan Africa].
    Sidibé el H
    Sante; 2007; 17(1):33-9. PubMed ID: 17897900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effect of radioactive iodine on thyroid function and size in patients with solitary autonomously functioning toxic thyroid nodules.
    Nygaard B; Hegedüs L; Nielsen KG; Ulriksen P; Hansen JM
    Clin Endocrinol (Oxf); 1999 Feb; 50(2):197-202. PubMed ID: 10396362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioiodine therapy of thyroid autonomy.
    Reiners C; Schneider P
    Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S471-8. PubMed ID: 12192548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Administration of additional inactive iodide during radioiodine therapy for Graves' disease: who might benefit?
    Dietlein M; Moka D; Reinholz U; Schmidt M; Schomäcker K; Schicha H; Wellner U
    Nuklearmedizin; 2007; 46(3):77-84. PubMed ID: 17549318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in the thyroid technetium-99m scintigram after antithyroid and subsequent radioiodine treatment for solitary autonomous nodules.
    Nygaard B
    Thyroid; 1998 Mar; 8(3):223-7. PubMed ID: 9545108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.